Saliva as a testing sample for SARS-CoV-2

detection by RT-PCR in low prevalence

community settings

Didzis Gavars[1], Mikus Gavars[1], Dmitry Perminov[1,4], Janis Stasulans[1],

Justine Stana[1], Zane Metla[1], Jana Pavare[3], Eriks Tauckels[1], Egils

Gulbis[1], Uga Dumpis[2,4]

1 - E.Gulbja Laboratory, Riga, Latvia

2 - Pauls Stradins Clinical University Hospital, Riga Latvia

3 - Children's Clinical University Hospital, Riga Stradins University,

Riga, Latvia

4 - University of Latvia, Riga, Latvia

Corresponding author:

Dr. Didzis Gavars, E.Gulbja Laboratory

Brivibas str.366, Riga, Latvia, LV-1006

email: didzis@egl.lv;

telephone: +37129259742; fax: +37167543867

Abstract

Objectives

The number of COVID-19 cases is increasing globally and there is an

urgency for a simple non-invasive method for the detection of SARS-

CoV-2. Our study aimed to demonstrate that saliva can be used as a

specimen for SARS-CoV-2 detection notably for the screening of

extensive population groups via pooling.

Methods

To demonstrate that saliva is an appropriate specimen for SARS-CoV-

2 detection a field study including 3,660 participants was performed

between September 29 and October 1, 2020. We collected paired

nasopharyngeal/oropharyngeal swabs (NPS) and saliva specimens and

processed them within 24 hours of collection. We performed 36 serial

measurements of 8 SARS-CoV-2 positive saliva samples to confirm

the stability of the specimen and completed 37 pools of saliva samples

by adding one positive specimen per pool.

Results

Saliva specimens were stable for testing for up to 24 hours. Overall,

44 salival samples (1.2%) tested positive for SARS-CoV-2 during the

field study. The results of saliva samples were consistent with those

obtained from NPS from the same patient with 90% sensitivity (95%

CI 68.3%-98.7%) and 100% specificity during the first two weeks after

the onset of symptoms. Using pooling strategy 796 RT-PCR tests were

performed. All pools showed 100% positivity in different pooling

proportions.

Conclusions

Our findings demonstrate that saliva is an appropriate specimen for

pooling and SARS-CoV-2 screening with accurate diagnostic

performance. Patient-performed simple specimen collection allows

testing an extensive number of people rapidly, obtaining results of the

spread of SARS-CoV-2 and allowing authorities to take timely

measures.

Introduction

Since the beginning of 2020 massive resources have been dedicated to

control and mitigate the COVID-19 pandemic. Testing capacity and

accessibility are crucial in monitoring COVID-19 outbreaks and

allowing for the adjustment of measures put into place to reduce

community transmission (1).

Viral nucleic acid detection using the real-time polymerase chain

reaction (RT-PCR) assay remains the gold standard for the detection

of SARS-CoV-2 and to diagnose COVID-19 (2). Due to the increased

demand for sampling and testing materials globally considerable

constraints remain to conduct widespread screening for SARS-CoV-2.

It is especially challenging for counties with low prevalence levels as

global suppliers allocate materials and decide delivery schedules based

on the prevalence of the virus.

Shortages of supplies and medical staff, logistical hurdles, as well the

unpleasantness associated with obtaining a RT-PCR specimen making

it difficult to practice the procedure on children and causing irritation

for those who need to undergo repeated tests, all these factors have

naturally accelerated research into alternative specimens and sampling

methods for COVID-19 testing (3,4).

On September 21, 2020, Latvia had a 14-day cumulative number of
COVID-19 cases of 5.1 per 100,000 people. By October 10 that
number had risen to 66. During this period, laboratories experienced a
significant overload (5). Rapid and efficient solutions to increase
testing capacity were needed.

The objective of this study was to confirm that saliva is a suitable
specimen comparable to a nasopharyngeal/oropharyngeal swab for
SARS-CoV-2 detection in specific populations. We also evaluated the
pooling approach to employ it in field conditions for extensive
screening of high-risk groups.

Methods

Patient sample collection

A single-center study was performed including all consented patients
attending the laboratory for SARS-CoV-2 testing between May 12 and
October 19, 2020. For the collection of the saliva samples, self-
collection kits were distributed consisting of a specimen vial,
registration form, alcohol pads for disinfection, and two safety plastic
bags. Patients were requested to collect their saliva in an isolated
location (keeping at least five meters distance from other persons or
objects), preferably outdoors, at home, or in their car. The saliva was
collected in a container without any additive and delivered to the
laboratory within 24 hours. Paired nasopharyngeal/oropharyngeal
swabs (NPS) for RT-PCR were collected using the standard method
used in our laboratory (6).

Sample preparation and analysis using RT-PCR

Immediately upon arrival at the laboratory, the samples were

pretreated by adding 1 ml of phosphate-buffered saline (PBS). The

extraction of RNA and RT-PCR testing was identical for both swab

and pre-treated saliva samples. Viral RNA was extracted with standard

commercial extraction methods (QIAGEN, Germany and LifeRiver,

China) used in our laboratory. RT-PCR was performed using our

laboratory-developed and validated test method which detects S and N

genes of the SARS-CoV-2 virus. Our validated and verified limit of

detection (LOD) was 1 cp/rxn.

Results

Stability of saliva specimens

To confirm the stability of saliva samples, we performed 36 serial tests

on 8 primary SARS-CoV-2 positive saliva samples collected from

patients 48 hours after their NPS tested positive. The data are

summarized in Tables 1-3. Testing was randomized by different time

intervals, the time of day, and the shifts of technicians. It includes

repeated testing of two samples after 22h (Table 2) and serial repeats

of one sample (Table 3) with Ct value reporting.

All results confirmed a positive result after 22-25h of the first test

being conducted. Samples were stored refrigerated at 2-6ºC between

tests.

Comparison of saliva and nasopharyngeal/oropharyngeal samples

Between May 13 and September 21, 2020, 431 tests on saliva samples

were performed, and the results were compared with paired NPS RT-

PCR test results. Using NPS RT-PCR as the reference, there were

104 PCR positive samples and 327 negative patients, including

125 pediatric (age 5-17 years (average 11.3 years)) samples. The

observed RT-PCR positive results were divided into groups according

to the number of days after the onset of symptoms: 0-14 days (22

patients); 15-30 days (52 patients); 31-70 days (20 patients) and

10 asymptomatic patients. The results of the comparison of the

mentioned subgroups are presented in Table 4.

Sensitivity and specificity for the respective groups were: for 0-14

days 90% (95%CI 68.3%-98.7%) and 100% (95%CI 22.4%-100%);

for 15-30 days 64.7% (95% CI 46.5%-80.3%) and 83.3% (95%CI

58.9%-96.4%); for 31-70 days 71.4% (95%CI 29.0%-96.3%) and

84.6% (95%CI 54.6%-98.1%); for asymptomatic 71.4% (95%CI

29.0%-96.3%) and 66.7% (95%CI 0.8%-90.6%). The mean Ct values

for the groups were 33.9 for NPS and 33.8 for saliva (0-14 days), 34.8

for NPS and 34 for saliva (15-30 days), and 36.5 for NPS and 39 for

saliva in the asymptomatic patient group.

Pooling of saliva

To evaluate the testing of pooled saliva samples, 37 pools were

constituted. There were 15 pools of 5 samples (4 negatives + 1

positive), 13 pools of 10 samples (9 negatives + 1 positive), and

9 pools of 20 samples (19 negatives + 1 positive). The RT-PCR testing

for each pool was repeated twice. The total number of measurements

was 74. All results were 100% positive.

When using pooling, the number of tests needed per sample was

calculated as follows: the total number of tests needed to test all

samples is divided by the total number of samples. For example, if

500 samples are being tested in pools of 10, it means 50 tests are

initially needed. With a positivity rate of 1%, a maximum of five pools

will contain a positive specimen (if each positive sample is in a

different pool). The 50 samples from these five pools will have to be

retested individually (each of the five positive pools contains 10

samples). Therefore, a total of 100 tests are needed to evaluate all

500 samples and the number of tests per sample is 100/500 = 0.2.

The positivity rate in Latvia on September 23, 2020, was 0.5%.

The approximate positivity rate at which the pooling of 5 samples

becomes more efficient than the pooling of 10 samples is 3% (2-4%

depending on test price, laboratory load, tests per sample).

Field study

To evaluate the convenience of saliva pool testing by RT-PCR in field

conditions, the town of Kuldiga (total population 10,352) with an

ongoing outbreak of COVID-19 in a textile factory was selected. In

collaboration with local authorities, 4,100 saliva self-sampling kits

were distributed to inhabitants at a specially established distribution

point. There were four persons dedicated to the distribution of the kits

and four drivers to deliver the samples by car to the testing laboratory

in Riga (150 km one way). During the study period, 3,660 saliva

samples were collected (response rate 91.5%), delivered to the

laboratory, and tested in pools of 10 samples. There were a total of

366 pools. In the first round of testing 43 pools were found to be

positive and samples from these pools were re-tested individually. The

saliva samples from 44 patients were confirmed as positive by RT-

PCR. Mean Ct values of pooled samples were 13% higher than

individually tested Ct (31.6 versus 27.6). The positivity rate of the

tested population was 1.2%. In total 796 RT-PCR tests were

performed. At the time of the sample collection, 68.2% (30/44) of

patients did not report any symptoms on the questionnaire form.

Nasopharyngeal swab tests and saliva tests were compared with the

number of new COVID-19 cases. The findings illustrate that the

second peak in new cases occurred 6-7 days after the initial peak. Such

findings correspond with the mean incubation period of the SARS-

CoV-2. The results reflect a decrease in new cases in the following

observation period (Figure 1).

Discussion

The findings of our study can be summarized as follows: (a) for the

detection of SARS-CoV-2, saliva is a stable specimen with acceptable

specificity and sensitivity at the early stages of infection; (b) saliva

specimen is appropriate for pooling, with accurate diagnostic

performance.

Saliva has been identified as a reliable testing specimen for SARS-

CoV-2 using the RT-PCR approach in several recent studies (7–9). In

the updated European Centre for Disease Prevention and Control

(ECDC) recommendations, saliva is also mentioned as a convenient

specimen for SARS-CoV-2 testing (10,11). The FDA has approved

methods for SARS-CoV-2 testing using saliva in several laboratories

(12,13). Nevertheless, saliva has been included in IFCC COVID-19

Guidelines on Molecular, Serological, and

Biochemical/Haematological Testing as a promising sample type (14).

The high expression of ACE2 receptors in salivary gland cells is the

main factor for virus affinity that could lead to active replication and

transmission by saliva droplets expelled into the air during coughing

or sneezing (15,16).

It is essential to establish standardized sample collection procedures,

safe logistics, and reliable testing methods that meet performance

requirements. Our stability testing confirmed that saliva samples

stayed equally positive up to 24h.

In the analytical context, saliva can have the same or even better

performance than NPS (17). It has been previously confirmed to be

highly sensitive and specific at the early stage of infection 0-14 days

after onset of symptoms and in asymptomatic cases (17,18). Therefore,

it is essential to take into consideration the relationship between the

dynamics of viral load, Ct values, and the number of days after the

onset of symptoms. As described in prior publications, the Ct value is

important in determining the infectiousness of a patient sample. Ct

values above 34 do not emit infectious virus particles, and values

between 27-34 show low viability of the viral load. Samples with a Ct

value of 13-17 show positive virus viability (19). Ct values may vary

depending on the different assays by up to 5 cycles for the same sample

(20). Variation also appears due to the quality of the specimen obtained

and the different treatment methods used to prepare samples for testing

(21). As expected, we got some variation between the NPS and saliva

sample types. In our pilot testing using 44 positive saliva samples we

found slightly higher (13%) Ct values in pools, compared to individual

tests. Similar findings have been published by other researchers (22).

This observed slight difference still allows for the safe use of saliva

pooling for surveillance purposes with sufficient diagnostic accuracy.

Nevertheless, pooling strategies are described in the latest update of

COVID-19 testing strategies and objectives published by the ECDC

(11). There is evidence of benefits from pooling in low prevalence

countries with a low proportion of positive samples – up to 5%. Recent

publications indicate that for populations with a prevalence of less than

1% the testing of saliva pools of 10 or 20 samples is more beneficial,

and our independent calculations also bear this out. Comparing the

correlation between different pool sizes (usefulness and efficiency)

with test positivity rate, we concluded that a pool size of 10 is more

efficient than a pool size of 5. The calculations are based on test price,

reimbursement conditions, and the number of tests per sample (when

using a pooling strategy) (23,24).

The pooling strategy for self-collected saliva samples is the optimal

solution that saves resources and reduces the testing time (25). In our

real-life field test on a "perifocal" population, we successfully tested

nearly a third of the citizens of the town of Kuldiga in three days. This

allowed for fast identification of asymptomatic SARS-CoV-2 cases

and those with mild symptoms to enable timely contact tracing and

outbreak containment. The use of nasopharyngeal swabs in such a

situation would have required more staff and time with possible patient

compliance issues.

Additionally, improvements may reasonably be expected in terms of

organizing the distribution of self-sampling kits to patients as well as

the logistics of returning the kits to the laboratory that would further

increase the usefulness of screening using a pooled testing strategy.

There were some limitations in our study: the size of the cohort of
participants was limited, the selected laboratory-developed RT-PCR
method for evaluation was used, also a lack of multicenter observation.
Future studies extending the cohort are needed to confirm current
findings and provide the implications in clinical practice.

Conclusions

Our findings confirm the stability of SARS-CoV-2 RNA in saliva,
showing acceptable performance in terms of specificity and sensitivity
at the early stages of infection, and the advantages of testing using a
pooling strategy in a low prevalence population. Ct values and
detected/missing gene information are favorable for the interpretation
of the results from several aspects, e.g. epidemiological investigation,
determination if the patient is infectious at the current stage, etc. Self-
sampling makes the procedure faster, safer, and requires fewer
resources. The targeted distribution of test kits among a population
with a known outbreak significantly increased the positivity rate.
Saliva pool testing on a large scale provides an additional tool to take
timely measures and contain outbreaks.

Ethical aspects

The study was approved by the Ethics Committee of the Pauls Stradins
Clinical University Hospital (record No 300720-18L).

Acknowledgments

We gratefully acknowledge all participants for their commitment to
participate and their time. Special thanks to all trial team members in
the E.Gulbja Laboratory for their dedication and work which made this
study possible and Dr. A.Gramatniece for editorial help.

Author contributions

Gavars D - the conception and design of the study, Gavars M,
Perminovs D, and Metla Z – validation of the method and
interpretation of the data, Stasulans J, Stana J - patient recruitment and
data collection, drafting of the article, Tauckels E - data analysis,
Gulbis E, and Dumpis U – revising the article critically, final approval
of the version to be submitted.

Transparency declaration

All authors declare that there are no conflicts of interest.

Funding institution:

Ministry of Education and Science, Republic of Latvia. Funding
number: VPP-COVID-2020/1-0008.

Additional funding was provided by E.Gulbja laboratory.

References:

1. Rapid Risk Assessment: Coronavirus disease 2019 (COVID-19)
in the EU/EEA and the UK– ninth update [Internet]. European

302  Centre for Disease Prevention and Control. 2020 [cited 2020 Nov

303  16]. Available from: https://www.ecdc.europa.eu/en/publications-

304  data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-

305  pandemic-ninth-update

306 2. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in

307  suspected human cases [Internet]. [cited 2020 Nov 16]. Available

308  from: https://www.who.int/publications-detail-redirect/10665-

309  331501

310 3. COVID-19: Overcoming supply shortages for diagnostic testing |

311  McKinsey [Internet]. [cited 2020 Nov 16]. Available from:

312  https://www.mckinsey.com/industries/pharmaceuticals-and-

313  medical-products/our-insights/covid-19-overcoming-supply-

314  shortages-for-diagnostic-testing#

315 4. Jeong HW, Kim S-M, Kim H-S, Kim Y-I, Kim JH, Cho JY, et al.

316  Viable SARS-CoV-2 in various specimens from COVID-19

317  patients. Clin Microbiol Infect. 2020 Nov;26(11):1520–4.

318 5. COVID-19 situation update for the EU/EEA and the UK, as of 16

319  November 2020 [Internet]. European Centre for Disease

320  Prevention and Control. [cited 2020 Nov 16]. Available from:

321  https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea

322 6. Marty FM, Chen K, Verrill KA. How to Obtain a Nasopharyngeal

323  Swab Specimen. N Engl J Med. 2020 May 28;382(22):e76.

324 7. Fakheran O, Dehghannejad M, Khademi A. Saliva as a diagnostic

325  specimen for detection of SARS-CoV-2 in suspected patients: a

326  scoping review. Infect Dis Poverty. 2020 Jul 22;9(1):100.

327 8. Hamid H, Khurshid Z, Adanir N, Zafar MS, Zohaib S. COVID-19

328  Pandemic and Role of Human Saliva as a Testing Biofluid in

329  Point-of-Care Technology. Eur J Dent [Internet]. 2020 Jun 3 [cited

330   2020 Nov 16]; Available from: http://www.thieme-
331   connect.de/DOI/DOI?10.1055/s-0040-1713020

9. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy Á, et al. Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis. Front Med. 2020 Aug 4;7:465–465.

10. Objectives for COVID-19 testing in school settings - first update, 21 August 2020. Tech Rep. 2020;4.

11. COVID-19 testing strategies and objectives [Internet]. European Centre for Disease Prevention and Control. 2020 [cited 2020 Nov 16]. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-testing-strategies-and-objectives

12. Commissioner O of the. Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens [Internet]. FDA. FDA; 2020 [cited 2020 Nov 16]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-using-home-collection-saliva

13. Rutgers Launches Genetic Testing Service for New Coronavirus | Rutgers University [Internet]. [cited 2020 Nov 16]. Available from: https://www.rutgers.edu/news/rutgers-launches-genetic-testing-service-new-coronavirus

14. Bohn M, Mancini N, Loh P, Wang C-B, Grimmler M, Gramegna M, et al. IFCC interim guidelines on molecular testing of SARS-CoV-2 infection. Clin Chem Lab Med. 2020 Oct 7;

15. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, et al. Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the

Upper Respiratory Tracts of Rhesus Macaques. J Virol. 2011 Apr

15;85(8):4025–30.

16. Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary Glands: Potential

Reservoirs for COVID-19 Asymptomatic Infection. J Dent Res.

2020;99(8):989.

17. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M,

Tokuyama M, Vijayakumar P, et al. Saliva or Nasopharyngeal

Swab Specimens for Detection of SARS-CoV-2. N Engl J Med.

2020;4.

18. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al.

Molecular and serological investigation of 2019-nCoV infected

patients: implication of multiple shedding routes. Emerg Microbes

Infect. 2020 Feb 17;9(1):386–9.

19. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C,

Colson P, et al. Viral RNA load as determined by cell culture as a

management tool for discharge of SARS-CoV-2 patients from

infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020

Apr 27;1–3.

20. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R,

Shrestha L, et al. Comparative Performance of SARS-CoV-2

Detection Assays Using Seven Different Primer-Probe Sets and

One Assay Kit. J Clin Microbiol. 2020 26;58(6).

21. Rodino KG, Espy MJ, Buckwalter SP, Walchak RC, Germer JJ,

Fernholz E, et al. Evaluation of Saline, Phosphate-Buffered

Saline, and Minimum Essential Medium as Potential Alternatives

to Viral Transport Media for SARS-CoV-2 Testing. McAdam AJ,

editor. J Clin Microbiol. 2020 May 26;58(6):e00590-20.

22. Lohse S, Pfuhl T, Berkó-Göttel B, Rissland J, Geißler T, Gärtner
B, et al. Pooling of samples for testing for SARS-CoV-2 in
asymptomatic people. Lancet Infect Dis. 2020 Nov
1;20(11):1231–2.

23. Regen F, Eren N, Heuser I, Hellmann-Regen J. A simple approach
to optimum pool size for pooled SARS-CoV-2 testing. Int J Infect
Dis. 2020 Nov 1;100:324–6.

24. Mutesa L, Ndishimye P, Butera Y, Souopgui J, Uwineza A,
Rutayisire R, et al. A pooled testing strategy for identifying
SARS-CoV-2 at low prevalence. Nature. 2020 Oct 21;1–8.

25. Fogarty A, Joseph A, Shaw D. Pooled saliva samples for COVID-
19 surveillance programme. Lancet Respir Med.
2020;8(11):1078–80.

Table 1 Run No. 1 on saliva stability measurements of 5 samples collected 2-4h before the first testing

	0	**after 8h**	**after 24h**	**after 25h**
	1st 14:00	*2nd 22:00*	*3rd 14:00*	*4th 15:00*
1	Positive	Positive	Positive	Positive
2	Positive	Positive	Positive	Positive
3	Positive	W- Positive	Positive	W- Positive
4	Positive	Positive	Positive	No sample left
5	Positive	W- Positive	Positive	W- Positive

Abbreviations: W-Positive - weak positive result, h - hours

Table 2 Run No. 2 on saliva stability serial measurements of two samples collected 2-4h before first testing

	0	after 12h	after 22h	after 22h rep.
	1st 12:00	*2nd 00:00*	*3rd 10:00*	*4th 10:00*
6	W- Positive	Positive	Positive	Positive
Ct	35	36	37	37
7	Positive	Positive	Positive	Positive
Ct	32	33	30	31

Abbreviations: W-Positive - weak positive result, rep. - repeats, h – hours

Table 3 Run No. 3 on saliva repeatability measurements of one sample collected 2 - 4h before the first testing with indicated Ct values

	0	after 3h	after 12h	after 24h
	1st 11:00	*2nd 14:00*	*3rd 02:00*	*4th 11:00*
8	Positive	Positive	Positive	Positive
Ct	34	30	33	35
8 rep.	Positive	Positive	Positive	Positive
Ct	34	27	31	35

Abbreviations: rep. - repeats, h – hours

Table 4 Saliva samples compared to the results of nasopharyngeal/ oropharyngeal swabs

Days after the start of symptoms		NPS							
		0-14		15-30		31-70		Asymptomatic	
RT-PCR		Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative
Saliva	Positive	18	0	22	3	5	2	5	1
	Negative	2	2	12	15	2	11	2	2
Sensitivity %		90		64.7		71.4		71.4	
Specificity %		100		83.3		84.6		66.7	

Abbreviations: NPS - nasopharyngeal/ oropharyngeal swabs, RT-PCR – real-time polymerase chain reaction